Widely available lysosome targeting agents should be considered as potential therapy for COVID-19 

Highlights
•  Lysosome targeting agents can disrupt endolysosomal maturation and inhibit viral replication •  Lysosome targeting agents and lysosomotropic drugs should be explored as antiviral drugs for severe acute respiratory syndrome coronavirus-2